CD163 Polypeptide Expression for PRRSV Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for propagating Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines rely on simian cell lines, which poses risks for xenotransplantation and lacks non-simian cell lines capable of supporting PRRSV replication, necessitating the identification of gene products conferring permissivity for PRRSV replication.
Innovation Solution
Increasing expression of the CD163 polypeptide in non-permissive cells through transfection, electroporation, or chemical induction to render them permissive for PRRSV infection, using methods such as transfection with nucleic acids encoding CD163 polypeptides or viral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If simian cell lines are used for propagating PRRSV vaccines, then vaccine production is achieved, but safety risks for xenotransplantation arise
Solution Approach 1:
The patent replaces permanent simian cell lines with disposable non-simian cell lines (porcine, bovine, ovine, caprine, or avian cells) that can be used for vaccine production without creating long-term safety risks. These cells serve as single-use or limited-use platforms that eliminate xenotransplantation concerns while maintaining vaccine production capability.
Solution Approach 2:
The patent introduces CD163 polypeptide expression as an intermediary mechanism to enable PRRSV replication in non-simian cells. By expressing the cellular receptor CD163 in these alternative cell lines, the virus can enter and replicate in cells that would otherwise be non-permissive, thereby providing a safe intermediate platform for vaccine production.
2Object-affected harmful factors
If non-simian cell lines are sought for PRRSV propagation, then safety risks are reduced, but currently no suitable cell lines exist
Solution Approach 1:
The patent changes the key parameter of cell line species origin from simian to non-simian (porcine, bovine, ovine, caprine, or avian), and simultaneously changes the expression level parameter of CD163 polypeptide in these cells. By transfecting these cells with nucleic acids encoding CD163, the expression parameter is adjusted to create permissive conditions for PRRSV replication, thereby expanding the availability of safe cell lines.
Solution Approach 2:
The patent performs preliminary action by pre-expressing the CD163 polypeptide in non-simian cell lines before virus infection. This preliminary expression of the cellular receptor prepares the cells to accept and support PRRSV replication, transforming them from non-permissive to permissive states in advance of vaccine production.
3Adaptability or versatility
If CD163 expression is increased in non-permissive cells, then permissivity for PRRSV replication is achieved, but additional transfection steps are required
Solution Approach 1:
The patent uses nucleic acids encoding CD163 polypeptide as an intermediary to transfer the permissivity trait to non-permissive cells. Rather than directly modifying the cells' complex biological systems, the approach introduces a specific genetic intermediary (CD163 gene) that mediates the change in permissivity, simplifying the overall modification process while achieving the desired effect.
Data Source
AI summary
The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.